Retatrutide’s side effects are dose-dependent and timed to titration: a gastrointestinal core it shares with semaglutide and tirzepatide, a burning or tingling skin sensation at the higher doses that the whole GLP-1 class can produce, and one effect that is more its own — a larger rise in heart rate, from the glucagon arm. Liver readouts are reassuring, and serious events are rare.¹ ⁵ ⁶
Who gets hit, and how hard, depends on the body as much as the dose. Retatrutide works through three receptors at once (a GIP / GLP-1 / glucagon triagonist), which spreads its side effects across three arms. The same 12 mg is a much larger dose per kilogram in a lean 77 kg body than in a 113 kg trial participant. That is why what users report does not line up with the trial tables.¹²
What Users Report Versus What the Trials Count
In the trials, gut symptoms lead every table: nausea, diarrhea, vomiting, constipation. Among real-world users they do not. A Reddit analysis of retatrutide posts found the most common self-reported symptoms were increased appetite, fatigue, and general malaise, then nausea and vomiting, with gut-motility complaints, muscle symptoms, insomnia, mood changes, and heart rate below them.¹⁰
The two rankings do not sit on the same scale. The Reddit figures are prevalence among the 7,823 posters who disclosed at least one mapped symptom, not incidence across an exposed trial arm, which over-weights whoever chose to post. The analysis cannot separate increased appetite while using retatrutide from appetite rebound after reducing or stopping it. What holds up is the shape: the real-world profile is not gut-led the way the trials are.¹⁰
The Same Milligrams, a Different Dose
A nominal 12 mg lands as a different exposure in each cohort. Divided by average body weight, 12 mg works out to 0.111 mg/kg in the Phase 2 obesity cohort, 0.122 in the lighter diabetes cohort, 0.140 in the lightest Phase 1b cohort, and about 0.157 mg/kg in a lean 77 kg self-doser — about 12% above the highest trial cohort and about 41% above the Phase 2 obesity cohort.¹²
Two things follow. The diabetes and Phase 1b cohorts sit at higher mg/kg than the obese cohorts at the same milligrams because they weigh less, yet their gut burden is not higher to match. The reason is that diabetes damps the response: years of high glucose blunt part of the incretin signal, which is the same effect that shows up as a quieter heart-rate rise in that cohort. Retatrutide’s high GIP-receptor potency pushes through some of it, which is why the glycemic benefit stays large while the side-effect burden does not scale with exposure.
A lean 77 kg self-doser at 12 mg sits above every trial cohort on this display — and unlike the diabetes cohorts, has no damping to offset it. That is the group the trial tables describe least well.² ³ ¹²
One reading rule: mg/kg over-corrects, and the true exposure gap across cohorts is narrower than the bars suggest. Use the chart for direction and rank, not exact ratios.
How much narrower is unmeasured. The correction everyone applies — clearance rising with body weight to the 0.8 power rather than in step with it — came from neither retatrutide nor tirzepatide data. Lilly’s tirzepatide population-PK model had 39,644 samples from 5,802 people and fixed that exponent at 0.8 rather than estimating it, citing a 2010 paper on therapeutic proteins in general. The FDA review restates the same structure, and every subgroup exposure ratio downstream inherits it. A number that could have been calculated from the data was borrowed instead, and it now sits underneath dose recommendations for the whole class.¹²
Which Receptor Is Behind Each Side Effect
The side effects sort by which arm is behind them. The gut burden — nausea, vomiting, diarrhea, constipation — is the incretin signature that retatrutide shares with semaglutide and tirzepatide (GLP-1 and GIP). It is dose-dependent and timed to titration.¹ ² ³
The heart-rate rise comes mostly from the glucagon receptor (GCGR), the arm the single- and dual-agonists effectively lack — tirzepatide reaches under 0.3% engagement there even at 15 mg, against roughly 12% for retatrutide at 12 mg. The burning-skin signal is a different story. It arrives at the same high doses, but it is not the glucagon arm: it is a GLP-1-receptor-class effect, and high-dose semaglutide, a GLP-1-only drug with no glucagon or GIP arm, carries it at comparable rates. The dysesthesia section below covers why.¹ ⁶ ⁷
GIP adds to the gut signal and also activates a separate inhibitory circuit in the brainstem that dampens nausea — which is why a drug engaging GIP heavily can be better tolerated per unit of appetite suppression than one that does not. The clinical pattern is measured independently of that mechanism: across nine incretin mimetics, longer escalation and more dose steps tracked greater nausea and vomiting tolerance, and within tirzepatide full escalation shifted the nausea and vomiting ED50 about fivefold. Time and steps are the levers with numbers behind them.¹³ ¹⁴
The Phase 3 Dose-Response
The Phase 3 obesity trial, TRIUMPH-1 (n=2,339), shows the dose-response with the least noise: nausea, diarrhea, vomiting, and constipation all climb from 4 to 12 mg, and discontinuation for side effects climbs with them.⁸
At 4 mg, discontinuation ran at 4.1% — below the 4.9% placebo rate — while still delivering substantial weight loss; by 12 mg it reached 11.3%. These are company-reported topline adverse-event counts.⁸
The one peer-reviewed Phase 3, TRANSCEND-T2D-1, runs lower gut rates in an early-diabetes population, but its placebo arm is not a clean baseline — those patients went untreated for diabetes, which runs hyperglycemia and rescue medication higher on placebo than on drug. Exact rates for all three trials are in the full tables below.⁴ ⁸ ⁹
Dysesthesia: The Skin-Sensation Signal
Dysesthesia is an abnormal skin sensation — burning, tingling, heightened sensitivity, sometimes pain from light touch — and it is the retatrutide side effect least familiar to users coming from semaglutide or tirzepatide. It is unfamiliar because most people on standard-dose semaglutide or tirzepatide never climb high enough to meet it, not because it belongs to retatrutide alone. It stays near placebo at low dose and climbs into the low-to-high teens at 9 to 12 mg.¹ ⁸ ⁹
The rates land around 12.3 to 12.5% in TRIUMPH-1 and 12.9% in Phase 2, and reach 20.9% at 12 mg in the knee-osteoarthritis trial, the highest in the program. TRIUMPH-4 jumps from 8.8% at 9 mg to 20.9% at 12 mg, where TRIUMPH-1 held nearly flat between the two.
Read across the whole program, the pattern is a step rather than a slope, and it sits at the 8-to-9 mg rung. Rates run near placebo at 1 mg (1.4%), reach roughly 6% at 4 mg, then jump to the 12 to 13% band at 9 and 12 mg. In exposure terms the break falls around 70 to 80 µg per kilogram of body weight — which is the number that transfers to a lighter body. At 70 kg, 9 mg delivers about 129 µg/kg, well past the break; the trial cohorts averaged 113 kg and reached 12 mg at about 107 µg/kg. A lighter person meets the high-rate band at a lower milligram figure than any trial arm did.
Two things could put TRIUMPH-4 highest. The first is cohort: TRIUMPH-4 enrolled only obesity with knee osteoarthritis, and knee-OA populations skew heavily female — TRIUMPH-1's own osteoarthritis subgroup was 75.8% female against 36.6% in its sleep-apnea subgroup. Women also receive more drug per kilogram under flat milligram dosing, since TRIUMPH-1's female participants averaged 105 kg against 128 kg for men, a 1.22-fold exposure difference at the same nominal dose. The second is ascertainment: a trial enrolling for a chronic pain condition asks about sensory symptoms more attentively, and OA participants may be more attuned to reporting them. The available toplines do not publish subgroup adverse-event tables, leaving these as competing explanations rather than a settled one — but the exposure arithmetic is measurable and points in a consistent direction.¹ ⁸ ⁹
Two candidate causes have already been ruled out, which narrows the field usefully. Weight loss itself is not the cause: in a cohort of 20,504 non-diabetic weight-loss users, skin allodynia ran about twice as often on a GLP-1 drug as on bupropion-naltrexone (adjusted hazard ratio 2.15) — an active comparator whose users are also losing weight.⁶ And the glucagon arm is not the cause: high-dose semaglutide engages no glucagon receptor at all and carries the strongest skin signal in the class. That leaves the GLP-1 receptor as the arm behind it.
What remains open is the downstream step. Human sensory-neuron experiments found enhanced ATP responses without direct nociceptor excitation or a TRPV1 effect, which makes selective ATP/P2X sensory amplification the working mechanism — a sensitization of existing pathways rather than new pain signaling, consistent with a sensation that is unpleasant but usually mild.⁷ Lilly reports dysesthesia as generally mild, rarely discontinuation-driving, and often resolving during treatment or after dose reduction.⁸ ⁹
Escalation speed appears to matter here as it does for the gut. The two matched 8 mg Phase 2 arms split 2.9% against 14.3% on dysesthesia — the slow ramp lower — which is 1 event against 5 on 35 participants each. Too few events to stand alone, but it points the same direction as the gastrointestinal escalation data below, where the same two arms split 16.7% against 36.9% on a far larger event count.¹
When the Gut Symptoms Hit, and How Hard
The week-by-week severity curve carries more than any week-48 total does: it shows when the burden peaks and whether it fades. Across the titration arms, gut trouble behaves as an escalation-step event, not a steady property of the dose: each arm’s peak lands within a few weeks of a dose increase, and most settle once the dose holds.¹
Peak severity scales with the dose and with how fast the climb was, and the peak arrives later as the target dose rises. One arm breaks the pattern: the fast 8 mg arm stayed elevated through week 48, the clearest sign in the study that a particular climb can leave a subgroup with persistent symptoms.¹
Why Climb Rate Is Its Own Variable
The two 8 mg arms in Phase 2 reach the same dose and the same 0.074 mg/kg by different routes. The arm that climbed slowly (2→4→8) peaked near 16.7% around week 11 and settled. The arm that jumped fast (a single 4→8 step) peaked at 36.9% around week 23 and was still elevated at 17.0% at week 48.¹ ¹²
Same final dose and nearly the same milligrams per kilogram, but a different climb changed how hard the side effects hit. GIP-mediated inhibitory signaling supplies the mechanism model. The measured conclusion does not depend on that model: the matched-final-dose retatrutide arms isolate climb rate, and the class analysis independently shows that more time and more steps build tolerance.¹ ¹³ ¹⁴
The class-level analysis puts a number on the adaptation effect. From first-in-human dosing to the fully escalated Phase 3 regimen, tirzepatide’s nausea ED50 rose from 15.6 to 78.7 mg per week and its vomiting ED50 from 43.3 to 209 mg per week — about a fivefold shift in both.
Across nine incretin mimetics, greater tolerance tracked longer escalation periods (r²=0.834) and more dose steps (r²=0.764); starting dose as a fraction of maintenance did not carry the same association (p=0.093).¹⁴
Why Lean, Healthy Users Get Hit Harder
Lean users can read louder on some instruments, but no single factor scales every effect the same way. It splits by system. On heart rate, the non-diabetic obese cohort shows a larger raw maintenance rise than the early-diabetes cohort at comparable doses. On gut effects, a lighter body carries more milligrams per kilogram, though mg/kg overstates the exposure gap. On blood sugar, only the diabetes cohort has high glucose to bring down.¹ ⁴ ¹²
A lean, healthy self-doser is more sensitive on some systems and not others. Heart rate is where it concentrates, and there the difference is large: roughly a threefold higher response ceiling reached at a sixth of the receptor occupancy. Gut burden runs modestly higher through exposure per kilogram. Blood sugar barely moves, because there is none to lower. Anyone applying a single multiplier across all three will get two of them wrong.¹²
Heart Rate, Read Through the Body
Retatrutide raises heart rate modestly and in step with the dose. In the obese Phase 2 cohort, raw in-clinic pulse changes at week 48 were +1.7, +3.1, +4.8, and +6.0 bpm at 1, 4, 8, and 12 mg.¹
The obese Phase 2 cohort reads +6.0 bpm on raw in-clinic pulse and +6.7 bpm on 24-hour monitoring at 12 mg; the early-diabetes Phase 3 cohort reads a raw +0.9 bpm at the same dose. Part of that gap is instrument and part is cohort: long-standing metabolic disease blunts the cardiovascular response, which is why the diabetes cohort reads lower despite carrying more drug per kilogram. Blood pressure fell while pulse rose. TRIUMPH-1 did not report heart rate, and the obesity Phase 3 figure remains anchored to Phase 2.¹ ⁴ ⁸
The mechanism is direct chronotropy, not adrenaline. Glucagon infused alone in humans raises heart rate 13.0 bpm, and still 9.2 bpm under beta-blockade, with heart-rate variability and norepinephrine both unchanged. Beta-blockers do not neutralize this effect the way they would a sympathetic one. That measured magnitude is three to four times the entire GLP-1-only class ceiling of 2 to 4 bpm, and unlike that ceiling it scales with dose.
The lean-versus-obese difference is quantified, not merely directional. The obese sedentary response curve tops out near 10 bpm and needs about half of glucagon-receptor capacity to reach halfway; the lean curve tops out near 33 bpm and gets halfway at roughly one-sixth that occupancy. At a shared 1 mg dose that reads as +0.7 bpm on ambulatory monitoring in the BMI-37 trial cohort against +10.3 bpm as an eight-day average in the lean Phase 1 cohort, peaking 15 to 20 bpm on days 4 to 6. Same milligram, same receptor occupancy, two different instruments — and the lean user has no large weight loss coming to pull the rate back down.
The Real-World Cohort Is the Lean Self-Doser
The Reddit cohort captures gray-market self-reporting rather than trial incidence. Its rank order emphasizes appetite, energy, insomnia, and heart rate ahead of many trial-counted gut events. Body weight and dose were incompletely reported, which leaves the dataset unable to establish that the rank shift comes predominantly from lean users or quantify their exposure.¹⁰ ¹²
The Serious Risks, and What No Trial Measured
Under the tolerability story sit the uncommon serious risks. An adjudicated case of acute pancreatitis appeared at 12 mg in Phase 2 — rare, but confirmed. Biliary events occurred in the program, and rapid weight loss is the established mechanism for gallstone formation across the whole weight-loss class, including bariatric surgery; the trials were not designed to attribute individual events. The single QT-prolongation event in Phase 2 is traceable to its cause: it occurred in a participant with severe vomiting and electrolyte loss, which is an electrolyte consequence rather than a direct electrophysiologic drug effect.¹ ⁵
The sharpest real-world danger is on no trial table at all. A published case report describes a 32-year-old man who bought retatrutide online, self-escalated to a chosen 20 mg weekly, then accidentally repeated the dose on consecutive days. Diarrhea started within hours — up to 30 watery bowel movements a day — and he reached the hospital with a racing heart, dehydration, low potassium, and acute kidney injury from fluid loss. He recovered with supportive care.¹¹
Two capture gaps matter. TRIUMPH-1 published no heart-rate result, and the obesity Phase 3 chronotropy figure is still inferred from Phase 2. And chills or temperature complaints show up in the Reddit dataset while remaining sparse in trial adverse-event reporting — a pre-specified inventory only counts what it was built to count.¹ ² ⁴ ⁸ ⁹ ¹⁰
Those cold complaints have a mechanism, and it decides which thyroid test to order. Heat production in brown fat is gated locally by DIO2, an enzyme that amplifies thyroid hormone three- to four-fold inside the tissue — not by the hormone level circulating in blood. Three retatrutide effects converge on that gate: FGF21 falls dose-dependently to −65.7% at 8 mg, and FGF21 supports DIO2 in thermogenic tissue; continuous glucagon engagement lowers T3 and raises reverse-T3 in humans with no TSH change; and the energy deficit itself suppresses the thyroid axis, the way 72 hours of fasting cuts T3 by roughly 30%. Two further routes skip thyroid entirely — GLP-1 raises skin and leg blood flow, shedding heat where cold is felt, and suppresses brown-fat activity through vagal signaling.¹⁵
Those routes predict different signatures, which makes them separable by one measurement pair. The thyroid route reads as Free T3 down and reverse T3 up with TSH unchanged, with cold skin and a widened gap between core and skin temperature. The perfusion route reads as an intact thyroid panel with skin that is warm to the touch but feels cold, and a narrowed gap. Timing helps too: the deficit route tracks how fast weight is coming off, the glucagon route tracks days after a dose step, and perfusion tracks injection timing.
The testing trap is TSH. Because the glucagon route moves T3 and reverse T3 without moving TSH, a TSH-first screen — the standard lab reflex — reads normal and stops. The panel has to name Free T3 and reverse T3 explicitly to see the inversion. One limitation runs the other way: DIO2 amplifies thyroid hormone locally, and a normal Free T3 narrows toward perfusion without completely excluding impaired heat production in the tissue.
Rising energy expenditure does not contradict the cold either: total energy burned, defended core temperature, peripheral heat loss, and thermal comfort are four separate variables, and a body can burn more while defending temperature worse.
A baseline panel makes later changes readable: resting heart rate across a week, fasting glucose and HbA1c, a lipid panel, and liver enzymes. Where cold or fatigue appears on drug, Free T3 and reverse T3 are the additions that carry information.
The Full Adverse-Event Tables
Every adverse-event rate carried above, read at full depth. All values are as reported; TRIUMPH rates are topline and provisional, while TRANSCEND-T2D-1 is peer reviewed.⁴ ⁸ ⁹
TRIUMPH-1 — non-diabetic obesity, week 80 (topline, provisional)⁸
| Adverse event (%) | Placebo | 4 mg | 9 mg | 12 mg |
|---|---|---|---|---|
| Nausea | 14.8 | 28.6 | 38.4 | 42.4 |
| Diarrhea | 13.5 | 25.2 | 34.1 | 32.0 |
| Constipation | 10.9 | 23.8 | 25.9 | 26.1 |
| Vomiting | 4.8 | 10.6 | 22.8 | 25.3 |
| Dysesthesia | 0.9 | 5.1 | 12.3 | 12.5 |
| Discontinuation (AE) | 4.9 | 4.1 | 6.9 | 11.3 |
TRIUMPH-4 — obesity + knee osteoarthritis, week 68 (topline, provisional)⁹
| Adverse event (%) | Placebo | 9 mg | 12 mg |
|---|---|---|---|
| Nausea | 10.7 | 38.1 | 43.2 |
| Diarrhea | 13.4 | 34.7 | 33.1 |
| Constipation | 8.7 | 21.8 | 25.0 |
| Vomiting | 0.0 | 20.4 | 20.9 |
| Dysesthesia | 0.7 | 8.8 | 20.9 |
| Discontinuation (AE) | 4.0 | 12.2 | 18.2 |
TRANSCEND-T2D-1 — early type 2 diabetes, week 40 (peer-reviewed)⁴
| Adverse event (%) | Placebo | 4 mg | 9 mg | 12 mg |
|---|---|---|---|---|
| Diarrhea | 4 | 19 | 26 | 23 |
| Nausea | 4 | 16 | 15 | 18 |
| Vomiting | 2 | 16 | 15 | 18 |
| Constipation | 1 | 4 | 8 | 4 |
| Dysesthesia | 0 | 4 | 2 | 4 |
| Discontinuation (AE) | 0 | 2 | 5 | 5 |
In TRANSCEND-T2D-1 the placebo arm is a diabetes population left untreated, which runs its hyperglycemia (26%) and rescue therapy (19%) higher than on drug. Read that column as an untreated-disease arm rather than a neutral baseline.⁴
Medical Disclaimer
The content in this retatrutide side-effects guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.
References
¹ Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. 10.1056/NEJMoa2301972. Figure S9A carries the weekly GI time course; the supplement carries adverse-event, pulse, and ambulatory-monitoring results. NCT04881760.
² Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. 10.1016/S0140-6736(23)01053-X. NCT04867785.
³ Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. NCT04143802.
⁴ Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. 10.1016/S0140-6736(26)00967-0. Week-40 raw pulse change: -0.1 / +1.5 / +0.9 bpm at 4 / 9 / 12 mg vs placebo -1.1. NCT06354660.
⁵ Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. 10.1038/s41591-024-03018-2.
⁶ Frey C, et al. Risk of allodynia with GLP-1 agonists. medRxiv. 2026 (preprint). Cohort of 20,504 non-diabetic weight-loss users; incident allodynia 35 vs 15 per 1,000 person-years against bupropion-naltrexone; adjusted HR 2.15 (95% CI 1.57-2.96). The active comparator reduces a weight-loss-only explanation but does not establish receptor causality.
⁷ Anand U, et al. GLP-1 receptor expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons. PLOS ONE. 2018;13(5):e0198024. Human dorsal-root-ganglion neurons showed enhanced ATP responses without direct nociceptor excitation or a TRPV1 effect; ATP/P2X amplification is a mechanism candidate, not a retatrutide dysesthesia experiment.
⁸ Eli Lilly. TRIUMPH-1 topline press release, May 21, 2026. Non-diabetic obesity, n=2,339, 80 weeks plus 104-week extension. Topline and provisional; full peer-reviewed results were not available for this page.
⁹ Eli Lilly. TRIUMPH-4 topline press release, December 11, 2025. Obesity with knee osteoarthritis, n=445, 68 weeks. Lilly investor release. Topline and provisional.
¹⁰ Sehgal NKR, Tronieri JS, Rader B, Ungar L, Guntuku SC. Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide. medRxiv. 2026 (preprint). 10.64898/2026.05.28.26352819. Among 13,589 self-reported current users, 7,823 had at least one mapped symptom after exclusions. This is prevalence among posting users, not exposed-population incidence.
¹¹ Komolafe O. Retatrutide-Induced Intractable Diarrhea. AIM Clinical Cases. 2026;5:e251218. 10.7326/aimcc.2025.1218. Corrected May 5, 2026, to clarify the diarrhea mechanism.
¹² Cohort weights, mg/kg normalization, and titration schedules — retatrutide explainer trial-normalized side-effects layer, derived from refs. 1-4. Mg/kg is a display normalization, not measured exposure, and overstates linear body-weight scaling.
¹³ GIP-receptor antiemetic circuit — Hayes MR, Borner T, De Jonghe BC. Diabetes. 2021; Zhang Q, et al. Neuron. 2021; Ludwig MQ, et al. Nature Metabolism. 2021; Borner T, De Jonghe BC, Hayes MR. American Journal of Physiology-Endocrinology and Metabolism. 2024;326:E528-E536. These sources support inhibitory brainstem signaling. They do not establish a weeks-long wiring interval in retatrutide-treated humans.
¹⁵ Thermogenic gating and the route-discriminating panel — local T3 in thermogenic tissue is gated by DIO2, which amplifies intracellular T3 three- to four-fold on sympathetic stimulation, with TRβ driving UCP1 from there. Converging retatrutide routes: FGF21 suppression (dose-ordered to −65.7% at 8 mg; FGF21 supports DIO2 expression); continuous GCGR engagement (glucagon lowers T3 and raises rT3 in humans with no TSH change); and energy deficit (72 h fasting cuts T3 approximately 30%). Thyroid-independent routes: GLP-1-mediated subcutaneous and leg blood-flow increase shedding heat at the skin, and peripheral GLP-1R suppression of brown-fat thermogenesis via vagal afferents. Acute glucagon raises energy expenditure approximately 150-240 kcal/day with GLP-1 co-administration preserving the rise (Beji & Caron 2026 Neuroendocrinology 116:157-172, p167) — production and defense are separate terms. Routes predict opposite signatures and are separable: thyroid route = cold skin, widened core-to-periphery gradient, T3 down / rT3 up; perfusion route = warm skin with cold sensation, narrowed gradient, thyroid panel intact; sensory-gain route = normal thermal measurements, shifted sensory thresholds. Onset timing separates further — deficit tracks weight-loss velocity, glucagon tracks days after a dose step, perfusion and sensory gain track injection timing. No retatrutide trial measured thyroid-axis endpoints; a Free T3 / rT3 panel plus a skin-versus-core gradient is the cheapest discriminating measurement available. TSH is unchanged on the glucagon route and is therefore the wrong screen; Free T3 and rT3 must be ordered explicitly.
¹⁴ Nauck MA, Punov V, Kang YM, Lim S. Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. Diabetes, Obesity and Metabolism. 2026;28(5):4232-4242. 10.1111/dom.70613. Nausea tolerance tracked escalation duration (r²=0.834; p=0.0010) and step count (r²=0.764; p=0.0045), while starting-dose fraction did not (p=0.093). Within tirzepatide, full escalation moved nausea ED50 from 15.6 to 78.7 mg/week and vomiting ED50 from 43.3 to 209 mg/week—about a fivefold shift. The result directly supports more time and more steps; it is not used to estimate retatrutide event rates.
---